Global biopharmaceutical company BioApp (CEO Eun-Joo Son ) announced that it signed a business agreement (MOU) with Organoid Science (CEO Jong-Man Yoo) for ‘organoid commercialization using plant-based recombinant proteins.’
Organoids are artificial organ-like structures created using stem cells and tissue engineering technology. They can be applied to patients with damaged functions of major organs or tissues, such as the heart, liver, and kidneys, and can be utilized for organ regeneration and incurable diseases.
As organoids are receiving attention as a key technology in the field of regenerative medicine, BioApp and Organoid Science plan to focus on research and development for commercialization of organoids through this business agreement.
In particular, BioApp, which possesses the technology for high protein expression and separation and purification using plants, plans to produce recombinant proteins necessary for organoids, such as growth factors, and Organoid Science plans to design and conduct experiments to verify this in an organoid model.
BioApp has a plant-based recombinant protein manufacturing platform and is currently producing growth factors and recombinant proteins for cultured meat media and collaborating with media and cultured meat companies. Cell culture is one of the core processes in the bio industry, and growth factors and recombinant proteins for cell culture are recognized as important raw materials, so the introduction of innovative technologies is urgently needed in various aspects, the company explained.
BioApp CEO Son Ju-seon said, “We hope that this business agreement will help commercialize organoid technology by supplying safe and economical green biomaterials using a plant-based recombinant protein production platform.”
- See more related articles
You must be logged in to post a comment.